mutLBSgeneDB
|
mutLBSgeneDB
mutated Ligand Binding Site gene DataBase
|
 Gene summary |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 : non-synonymous mutation on LBS, Circle size denotes number of samples. |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples |
K388 | L387I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
(ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change |
K388 | L387I | -0.48698757 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for INHBA from PDB |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0032914 | Pre-Eclampsia | 2 | AlteredExpression, Biomarker |
| umls:C0023267 | Leiomyoma | 1 | Biomarker |
| umls:C0162557 | Liver Failure, Acute | 1 | Biomarker |
| umls:C0042138 | Uterine Neoplasms | 1 | Biomarker |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
| Ligands binding to mutated ligand binding site of INHBA go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Multiple alignments for P08476 in multiple species |
| LBS | AA sequence | # species | Species |
C390 | ANLKSCCVPTK | 5 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus | C390 | NGMRPCCAPIK | 1 | Drosophila melanogaster | K388 | PFANLKSCCVP | 5 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus | K388 | -MNGMRPCCAP | 1 | Drosophila melanogaster | S13 | GFLLASC---- | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | S13 | CFFNCQCICCR | 1 | Drosophila melanogaster | S13 | GFLLVIC---- | 1 | Gallus gallus | S389 | FANLKSCCVPT | 5 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus | S389 | MNGMRPCCAPI | 1 | Drosophila melanogaster |
